Biotie Therapies Oyj : Biotie: Selincro (nalmefene) receives European marketing authorization

    Biotie Therapies Oyj : Biotie: Selincro (nalmefene) receives European
                           marketing authorization

BIOTIE THERAPIES CORP.   STOCK EXCHANGE RELEASE   28 February 2013 at
12:00

Biotie: Selincro (nalmefene) receives European marketing authorization

Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has received
European marketing authorization from the European Commission for Selincro
(nalmefene; an opioid system modulator) for the reduction of alcohol
consumption in adult patients with alcohol dependence. The marketing
authorization applies to all 27 European Union member states.

Timo Veromaa, President and CEO: "This is very good news to the patients
suffering from alcohol dependence and a most significant milestone for Biotie
as a drug development company."

Lundbeck will provide Selincro as part of a new treatment concept that
includes continuous psychosocial support focused on the reduction of alcohol
consumption and treatment adherence. Subject to the completion of pricing and
reimbursement discussions, Lundbeck expects to launch Selincro in its first
markets in mid-2013.

Turku, 28 February 2013

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Timo Veromaa President and CEO
tel. +358 2274 8900, email: timo.veromaa@biotie.com

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd

Main Media

ABOUT SELINCRO (nalmefene):

Selincro is indicated for the reduction of alcohol consumption in adult
patients with alcohol dependence who have a high drinking risk level (>60
g/day for men, >40 g/day for women) without physical withdrawal symptoms and
who do not require immediate detoxification. Selincro should be prescribed in
conjunction with continuous psychosocial support focused on treatment
adherence and the reduction of alcohol consumption. Treatment should be
initiated only in patients who continue to have a high drinking risk level two
weeks after an initial assessment. Selincro is to be taken as-needed; that is,
on each day the patient perceives a risk of drinking alcohol, one tablet
should be taken, preferably 1-2 hours prior to the anticipated time of
drinking.

Biotie has licensed global rights to Selincroto Lundbeck. Under the terms of
the agreement, Biotie is eligible for up to EUR 89 million in upfront and
milestone payments plus royalties on sales of Selincro. Biotie has previously
received EUR 12 million of such milestone payments from Lundbeck. Further
milestone payments are expected on commercial launch of Selincro and on the
product potentially reaching certain predetermined sales. Lundbeck is
responsible for the registration, manufacturing and marketing of the product.

ABOUT BIOTIE

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's
disease, Alzheimer's disease and other cognitive disorders, alcohol and drug
dependence (addiction) and post-traumatic stress disorder), and inflammatory
and fibrotic liver disease. The company has a strong and balanced development
portfolio with several innovative small molecule and biological drug
candidates at different stages of clinical development. Biotie's products
address diseases with high unmet medical need and significant market
potential.

Biotie's most advanced product, Selincro (nalmefene), licensed to H. Lundbeck
A/S, has on 28 February 2013 received European marketing authorization for the
reduction of alcohol consumption in adult patients with alcohol dependence who
have a high level of alcohol consumption. In addition, Biotie has a strategic
collaboration with UCB Pharma S.A. covering tozadenant which has successfully
completed a Phase 2b study in 420 patients with advanced Parkinson's disease.
Biotie shares are listed on NASDAQ OMX Helsinki Ltd.

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Biotie Therapies Oyj via Thomson Reuters ONE
HUG#1681977